Technology

INmune Bio

$20.35
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.36 (+1.77%) Today
-$0.37 (-1.79%) As of 1:32 PM UTC after-hours

Why Robinhood?

You can buy or sell INmune Bio and other stocks, options, and ETFs commission-free!

About INMB

INmune Bio, Inc. focuses on controlling components of the immune system to activate an immune response against cancer and Alzheimer’s disease. Its product pipeline INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer, and LIVNATE. The company was founded by Mark Lowdell in September 2015 and is headquartered in La Jolla, CA. The listed name for INMB is INmune Bio Inc. Common stock.

CEO
Raymond J. Tesi
Employees
4
Headquarters
La Jolla, California
Founded
2015
Market Cap
343.79M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
625.42K
High Today
$23.99
Low Today
$20.27
Open Price
$20.71
Volume
1.10M
52 Week High
$29.99
52 Week Low
$2.20

Collections

INMB Earnings

-$0.36
-$0.24
-$0.12
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 11, After Hours

You May Also Like

CFRUY
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure